

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1. (Currently amended) A method of manufacturing IgG4 immune globulin that has a decreased risk of aggregation and fragmentation, said method comprising comprises the steps of:

(a) adjusting plasma to a pH of about 6.5 and a conductivity of between 3.5 to 6 millisiemens;

(b) contacting the plasma obtained from step (a) with an anion exchange resin to obtain an anion exchange effluent; and

(c) contacting the effluent of step (b) with a cation exchange resin to obtain a cation exchange effluent that comprises IgG4 essentially free of other IgG subtypes.

2-4. (Cancelled)

5. (Previously presented) The method of claim 1, wherein said plasma is plasma obtained from an immune donor.

6. (Previously presented) The method of claim 1, wherein said anion exchange resin comprises Sepharose and a diethyl aminoethyl ion exchange group.

7. (Previously presented) The method of claim 1, wherein said cation exchange resin comprises Sepharose and a carboxy methyl ion exchange group.

8. (Previously presented) The method of claim 1, further comprising the steps of:

(d) adding NaCl to a final concentration of 0.03 to 0.05 M NaCl;

(e) filtering the solution of step (d);

(f) centrifuging the filtrate of step (e);

(g) freezing the supernatant of step (f);  
(h) thawing the frozen supernatant of step (g);  
(i) adding a monosaccharide or disaccharide to the thawed supernatant of step (h)  
to a final osmolarity of between 0.22 to 0.35 OsM;  
(j) filtering the solution of step (i);  
(k) freezing the filtered solution of step (j);  
(l) thawing the frozen solution of step (k); and  
(m) lyophilizing the solution of step (l).

9. (Previously presented) The method of claim 8, wherein said monosaccharide is lactose.

10-13. (Cancelled)